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Melanoma is one of highly aggressive kinds of skin cancer with a meta-
static potential. Currently, melanoma treatment has been improved by
a combination of therapies with targeted kinase inhibitors and immunother-
apies, with radiation therapy (RT) reserved to the most advanced melanoma
stage. Among different RT options, the Boron Neutron Capture Therapy
(BNCT) is a modality which selectively destroys tumor cells leaving healthy
ones almost intact. Its therapeutic effect depends mainly on the boron con-
centration in a cancer. Therefore, there is a need to find a ligand which
transfers sufficient amount of boron to cancer cells and study their poten-
tial therapeutic activity in preclinical studies. Spheroids, which are 3D cell
models are proposed to test nucleic acids as a boron carrier for BNCT to
mimic 3D structure and microenvironment of cancer.
DOI:10.5506/APhysPolB.51.413
1. Introduction
Melanoma is one of the most aggressive types of skin cancer and its
occurrence continues to rise worldwide. Global melanoma incidence is es-
timated to 1.7% of all new diagnosed melanomas and 0.7% of all cancer
deaths are resulted by cutaneous melanoma annually [1, 2]. Melanoma is
caused by neoplastic transformation of melanocytes, highly specialized skin
cells producing pigment — melanin (dark eumelanin and reddish pheome-
lanin). Despite over 95% of melanomas are developed in the skin, they
can also be found in other parts of a human body like eyes, mucous mem-
branes of the nose, mouth, or less often in vagina and anus. In cancer
development, two factors play an important role: environmental exposure
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(UV light) and genetic predispositions [2, 3]. Different mutations are respon-
sible for melanoma transformation among them, two are commonly found
in melanomas: BRAFV600E and NRASQ61, in about 40% and 20% of cases
respectively [1]. Melanoma treatment is determined by many factors, but
the prime and most important are the size and stage of the cancer. There
are several therapy modality options: surgery, chemotherapy including bi-
ological and targeted therapy, and radiotherapy, which is currently used in
a terminal stage of this disease. There is a need to develop and introduce
alternative strategies to treat melanoma in late stages successfully. In such a
case, the Boron Neutron Capture Therapy (BNCT) could be the best option
to save patient life or extend a surviving rate [4].
2. Boron neutron capture therapy
Selective accumulation of 10B in tumor cells and irradiation with thermal
neutrons destroys only the cancer without serious damage to adjacent normal
cells. The main limitation of this therapy is the lack of a selective and
efficient boron carrier to transfer a boron atom to a cancer cell directly
and selectively. Currently used boron carriers are not perfect and there is
a need to find a better one to increase the success rate of the BNCT therapy
and decrease side effects in healthy tissues of a patient [5]. In the BNCT
therapy, a non-radioactive boron isotope is injected into patient’s body. This
isotope is uptaken mainly by cancer cells, which is associated with increased
metabolism of these cells. Next, the patient is irradiated by neutron beam.
Thanks to high cross section for thermal neutron capture on boron, the
dose is deposited mainly in the cancer cells. The products of the neutron
capture on 10B reaction have a high linear energy transfer and a low range
(< 10 µm), hence the energy deposition is limited to the diameter of a single
cell (Fig. 1). Therefore, it is possible to selectively destroy only tumor cells
while leaving the normal ones intact within a body [6, 7].
The important limitation which affects the efficiency of BNCT is obtain-
ing a sufficient number of boron atoms deposited within each cancer cell.
Therefore, the boron delivery system is crucial for the BNCT therapy. Main
objective of current research is finding a suitable model to test a boron car-
rier which could increase its uptake only by tumor cells. Spheroids, which
are 3D cell culture models are proposed for such testing allowing to perform
this kind of research apart from animal tests.
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Fig. 1. Schematic representation of the reaction of neutron capture on 10B. Figure
adopted from [6].
3. Boron carriers and conveyors
From biological and clinical point of view, the best carrier should be non-
toxic for cells. A good proportion of its accumulation in tumor and healthy
cells is also very important (> 3 : 1). Such a carrier should be quickly re-
moved from patient’s body, on the other hand, should also persist in cancer
cells during irradiation with a proper concentration (∼ 20–50 µg 10B/g) [8].
Currently the BNCT therapy employs mostly two boron carriers: sodium
mercaptoundecahydro-closo-dodecaborate (BSH, Na102 B12H11SH) and
boronophenylalanine (BPA). Both of them have, however, their limitations,
they accumulate inside cells with low efficiency or stuck outside them. There-
fore, there is a need to develop new carriers to improve a system which could
provide the sufficient boron inner concentration inside a tumor cell. To ac-
complish this purpose, several new approaches have been established. Over
the last years boron delivery system development has taken two directions:
boron carriers and conveyors. Boron carriers include carboranes, amino
acids, growth factors or monoclonal antibodies [4, 8, 9] (Fig. 2).
On the other hand, liposomes are very promising conveyors to transfer
boron carriers into a cell [8]. Due to their structure, hydrophilic and hy-
drophobic molecules such as proteins, RNA, DNA, enzymes, vaccines and
imaging agents can be carried by them. Two types of liposomes are in use:
one to encapsulate radioactive agent inside, the other to incorporate active
lipophilic substance to bilayer of liposomes and utilize them to transport
these compounds to different places in the patient’s body. They have nu-
merous unique properties as drug delivery system including biocompatibil-
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Fig. 2. Different kind of boron carriers. (1)N5-2OH (3-[5-{2-(2,3-dihydroxyprop-
1-yl)-o-carboran-1-yl}pentan-1-yl] thymidine) is a carboranyl thymidine ana-
logue (CAT). (2) cis-ABCHC and trans-ABCHC (1-amino-3-borono-
cycloheptanecarboxylic acid). (3) C225-G5-B1000 is a heavily boronated form of
the monoclonal antibody cetuximab that specifically targets the human epidermal
growth factor receptor (EGFR). (4) H2-DCP (di [3,5-(nido-carboranylphenyl)
tetra-benzoporphyrin]) is one of a group of carboranyl porphyrins containing
multiple carborane clusters. Figure adopted from [8].
ity, biodegradability, low toxicity and immunogenicity, ability to carry large
drug cargo. It is possible to modify the surface of liposomes with ligands
for site-specific delivery of drugs to determined cell types. Such ligands
may be proteins, peptides, antibodies or carbohydrates [10, 11]. Peacock
et al., in [12] synthesized a new cholesterol–carborane conjugate as a poten-
tial targeting agent for BNCT. This compound was carried by liposomes,
resulted in adequate cellular uptake. It was proven that cellular uptake
depends on concentration of cholesterol–carborane conjugate in the media
and also on confluence of the cells. Nonconfluent cells uptake boron better,
which indicates that active cell growth has influence on the uptake of this
compound [12].
Testing of boron carriers requires an appropriate research model. Due to
the future use of carriers in the treatment of cancer, the model should be as
similar to the tumor as possible. Spheroids have a lot of features allowing
them to mimic structure and microenvironment of the cancer. Structure of
spheroids, as in tumors, consist of different cell layers. The external layer
is generated by cells with high proliferation rates, which have unlimited ac-
cess to nutrients and oxygen. In the center of spheroid, a necrotic zone is
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observed. It is caused by conditions that prevail inside the spheroid (hy-
poxia and lack of nutrients). Another similarity is a possibility of making an
intercellular membrane contact by desmosomes, gap junction and extracellu-
lar matrix (ECM) production. This kind of cell–cell signaling and presence
of ECM makes the organization and structure of spheroid stable and more
resistive to radiation [13, 14]. Spheroids have a similar growth pattern to
tumors. Firstly, a volume of spheroids increases exponentially then, when
the diameter reaches 200–500 µm it enters a plateau state. Molecular studies
have shown alike gene expression pattern in spheroids and tumors. There
are mostly genes that are responsible for cancer progression, invasion and
metastatic as chemokines, cell-adhesion molecules and pro-angiogenic fac-
tors [13]. All these attributes make them a good model to test effectiveness
of a boron carrier.
4. Melanoma and boron nucleic acid carrier
About 40% of all melanomas have mutation in the BRAF gene which
produces a protein — kinase B, Rapidly Accelerating Fibrosarcoma. This
protein played significant a role in cells growth and regulating proliferation.
Therefore, it is very important in healthy cells, and the mutation in BRAF
gene causes uncontrolled proliferation of cells and tumor development [1],
see Fig. 3.
Fig. 3. Formation of tumor. Scheme of differences in growth of a healthy and
tumor cell. In a healthy cell the BRAF protein is one of the enzymes which is
involved in transmission of the cell growth and division signal. A mutation in this
gene disrupts function of BRAF protein which causes uncontrolled cell growth and
division. Figure adopted from [15].
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Leśnikowski et al. have focused their research on nucleic acids and oligo-
nucleotides application as potential boron carriers for BNCT
[16–18]. In their research, a few important features of this carriers such as
low cytotoxicity, increased lipophilicity, and formation of stable heterodu-
plexes with complementary RNA strains were proven. In another approach,
impact on various boron clusters incorporated into the structure of nucleic
acid at specific locations was examined. They showed also that oligonu-
cleotides with boron clusters may have an additional role like silencing ac-
tivity, redox active labels for electrochemical detection of DNA [16]. Boron
clusters were tested to modify siRNA directed toward the gene encoding
BACE1. This gene produces protein contributing to the formation of pep-
tides, which is identified in amyloid plaques of patient with Alzheimer’s
disease. According to the amyloid cascade hypothesis, inhibition of produc-
tion protein encoding by BACE1 may be one of the approach for Alzheimer’s
disease treatment. It could be possible by blocking the expression of BACE1
by appropriate siRNA [18].
In the current project, boron carrier based on nucleic acid will be used.
A working hypothesis assumes that sequences with mutation in BRAF gene
[19, 20] could serve as templates to synthesize oligonucleotide containing
a boron cluster [18]. This oligomer would be preferentially combined with
melanomas DNA, due to the presence of the same mutation. It is planned
to use the synthetic RNA oligonucleotides which are complementary to par-
ticular, selected several BRAF mutations and conjugate them with a boron
cluster. These boron-loaded antisense RNA-oligonucleotides will be encap-
sulated in liposomes and tested with utilized spheroids. Examination of
viability and DNA fragmentation in spheroids after neutron irradiation is
planned. Evaluation of BNCT effectiveness using this type of boron carrier
on spheroids as a model of cancer cells is intended.
5. Summary
In conclusion, increase in cancer incidence and resistance to some treat-
ments demands a new modality of tumor treatment or refinement of existing
ones. One of the possible new therapies there is the BNCT, which needs an
improvement in the boron delivery to the tumor cells. This can be reached
through increasing of the selectivity of boron carrier to cancer cells by using
a carrier with a nucleic acid complementary to the mutation in melanoma
cells. Application of spheroids may provide a model as close as possible to
the conditions prevailing in the tumor.
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